The findings of these analyses supported a key role for NF-κB in astroglia-driven neurodegenerative inflammation in experimental glaucoma, thereby pointing to astroglial NF-κB as a favorable treatment target to provide immunomodulation for neuroprotection in glaucoma. This evidence concerns the gene NFKB1 and glaucoma.